Table 5.

Correlations between Δlog glucose infusion rate and metabolic or anthropometric parameters before the administration of empagliflozin.

Variables	Δlog glucose infusion rate
	Total (n = 20)		BMI <25 kg/m2 (n = 9)		BMI ≥25 kg/m2 (n = 11)
	r	P-value	r	P-value	r	P-value
Age, years	−0.33	0.16	0.38	0.31	−0.43	0.18
Diabetes mellitus duration, years	−0.27	0.031a	0.15	0.70	−0.62	0.041a
BMI, kg/m2	0.35	0.13	−0.46	0.22	0.24	0.48
Body fat mass, kg	0.44	0.0495a	0.43	0.25	0.30	0.37
Skeletal muscle mass, kg	0.094	0.69	−0.30	0.43	−0.04	0.91
HbA1c (IFCC: mmol/mol)	0.04	0.88	0.64	0.066	−0.26	0.44
Fasting PG level, mmol/L	0.12	0.62	−0.27	0.48	0.15	0.66
HOMA-IR	0.51	0.023a	0.61	0.080	0.45	0.17
s.d. value in PG profiles	0.011	0.96	−0.71	0.033a	0.30	0.37
Urinary glucose excretion, g/day	−0.19	0.42	−0.34	0.34	−0.22	0.52
Aspartate transaminase, IU/L	0.49	0.029a	0.72	0.030a	0.34	0.31
Alanine transaminase, IU/L	0.55	0.013a	0.83	0.0052a	0.47	0.15
Serum uric acid, µmol/L	−0.12	0.62	0.031	0.94	−0.57	0.070
HDL-cholesterol, mmol/L	−0.027	0.91	0.039	0.92	0.055	0.87
Triglyceride, mmol/L	−0.0017	0.99	0.26	0.50	−0.21	0.52
LDL-cholesterol, mmol/L	−0.19	0.43	0.027	0.94	0.27	0.41

Statistical significance determined via Pearson’s correlation coefficient. Values in bold ^a indicate P < 0.05.

HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; LDL, low-density lipoprotein; PG, plasma glucose.